Poster ID - P0216

EAU THERMALE Avène
LABORATOIRE DERMATOLOGIQUE

Tolerability and efficacy of an emollient "Plus" containing *Aquaphilus Dolomiae* and Dextran sodium sulfate extracts in improving long-term atopic skin condition of infants and children

Hélène Ghienne[1], Camille Boudet[2], Gautier Doat[2], Marie-Dominique Thouvenin[1]

1 R&D Department, Pierre Fabre Dermo-Cosmetics & Personal Care, Toulouse, France

2 Medical Department, Laboratoires Dermatologiques Eau Thermale AVENE, Pierre Fabre Dermo-Cosmetics & Personal Care, Lavaur, France

Introduction & Objectives

Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder in infants and children, with a significant impact on the quality of life.

Emollients are considered as the first-line therapy of AD management. Their prolonged application has been shown to improve skin condition, patient's quality of life and space-out flare-ups. These products must be safe, effective, and suitable for infants and children.

This study aimed to assess the tolerability and efficacy of an emollient "Plus" containing *Aquaphilus Dolomiae* and Dextran sodium sulfate extracts, intended to improve long-term atopic skin condition.

Materials & Methods

STUDY DESIGN

A 6-month-open clinical study.
Product applied twice a day on face & body.

POPULATION

33 subjects:
- **12 infants** (3 to 23 months)
- **21 children** (24 months to 11 years old)

MAIN INCLUSION CRITERIA

- Mild atopic dermatitis with SCORAD between 10 and 24
- Xerosis intensity ≥ 2 (0–3 scale: 0= none, 1= mild, 2= moderate, 3= severe)
- Pruritus intensity ≥ 3 (average from 3 last days, Visual Analogue Scale 0–10)
- At least 1 peak of xerosis & pruritus per month during the 3 previous months reported by parents


MAIN ASSESSMENTS


- **AD severity**
  SCORAD index
  including xerosis & pruritus
- **Quality of life**
  Dermatology Life Quality Index
  for children (CDLQI) & infants (IDQOL)
- **Number of peaks of xerosis & pruritus**
- **Tolerability**
- **Cosmetic acceptability**


Results

AD Severity

Significant improvement of clinical parameters at each timepoint.







Tolerability

Tolerability was assessed as **very good by the investigators** (dermatologist & pediatrician).

Cosmetic acceptability


The cosmetic acceptability of the product was **very good**.
After 6 months of use, children and infants' parents declared that **the quality of their child's sleep had improved (9.0/10).**

Number of peaks of xerosis & pruritus


While at baseline, subjects/parents reported a mean number of 8 peaks of xerosis & pruritus during the 3 previous months, **almost all (94%) did not report any peak during the study**.

Quality of life

Significant improvement of quality of life at each timepoint.



After 6 months of twice-daily use on face and body, **highly statistically significant improvement of 96% of the quality of life for children.**



After 6 months of twice-daily use on face and body, **highly statistically significant improvement of 76% of the quality of life for infants.**

Conclusion

The efficacy results of this study demonstrate the benefit of an emollient "Plus" in improving the long-term management of atopic skin condition in infants and children. Moreover, its very good tolerability and acceptability by the subjects and their parents could help to ensure long-term compliance.

Presented at the European Academy of Dermatology and Venereology Annual Congress, 30 September to 3 October 2026, Vienna, Austria